DSIP vs PT-141 (Bremelanotide)

DSIP: Endogenous nonapeptide that promotes delta wave sleep and modulates neuroendocrine stress responses. Typical dose 100-300 mcg. PT-141 (Bremelanotide): FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Typical dose 1000-2000 mcg. Both fall under the Sleep and Sexual Health categories.

Stacking DSIP with PT-141 (Bremelanotide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

DSIP is typically dosed: Once daily, 30-60 minutes before bedtime (SubQ) for Sleep support; Once daily (SubQ) for Stress and cortisol modulation. PT-141 (Bremelanotide) is typically dosed: As needed, at least 45 minutes before activity for HSDD treatment (FDA-approved dose); As needed, 45-60 minutes before activity for General sexual function enhancement.

DSIP: Not FDA approved for human use. No clinical trials submitted for FDA review. PT-141 (Bremelanotide): FDA approved. Bremelanotide (Vyleesi) was approved in June 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.